This product is intended exclusively for research and laboratory purposes (in vitro). It is not intended for diagnostic, therapeutic, food, cosmetic, veterinary or supplement use.
Purchases may be made only by adults. The buyer confirms appropriate knowledge and qualifications for safe handling of research chemicals.
Product description
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, which was isolated from the cerebral venous blood of rabbits in 1977 by the group of Schoenenberger and Monnier in Basel. The peptide received its name because of early observations suggesting its ability to induce slow-wave sleep (delta phase) in experimental animals.
Structurally, DSIP is an amphiphilic peptide with a molecular mass of 850 Da, characterized by a unique amino acid pattern not assigned to any known peptide family. The molecule shows low molecular stability in vitro, with a half-life of about 15 minutes due to the action of a specific aminopeptidase. It has been suggested that in the body DSIP forms complexes with carrier proteins or exists as a fragment of a larger precursor, although no gene or precursor protein has been identified to date.
DSIP has been detected in both free and bound forms in the hypothalamus, limbic system, pituitary gland, and various peripheral organs, tissues, and body fluids. In the pituitary gland it colocalizes with many peptide and non-peptide mediators, including CLIP, ACTH, MSH, TSH, and MCH. It is also present in secretory intestinal cells and in the pancreas, where it colocalizes with glucagon. DSIP-like material has been detected in human breast milk.
Despite almost 50 years of research, the biological function of DSIP remains enigmatic. Evidence for its association with sleep patterns is contradictory — some studies suggest promotion of slow-wave sleep and suppression of REM sleep, while others show no correlation. Stronger effects on sleep have been observed for synthetic DSIP analogues with greater molecular stability.
Modulation of neurotransmitter synthesis — DSIP affects neurotransmitter levels in the brain by acting on noradrenergic, serotonergic, and dopaminergic pathways. Some studies have demonstrated stimulation of acetyltransferase activity through α1-adrenergic receptors. This modulation may contribute to effects on sleep and mood.
Interaction with NMDA receptors — In the brain, DSIP activity may be mediated by NMDA (N-methyl-D-aspartate) receptors, which are crucial for learning, memory, and synaptic plasticity processes. This interaction may explain some of the peptide’s neuroprotective effects.
Regulation of the hypothalamic-pituitary axis — Evidence indicates that DSIP is regulated by glucocorticosteroids and may interact with components of the MAPK cascade. The peptide shows homology to glucocorticoid-induced leucine zipper (GILZ), which prevents Raf-1 activation and inhibits ERK phosphorylation.
Stress-protective action — DSIP shows the ability to counteract stress by modulating levels of substance P, β-endorphin, and corticosterone. In studies in rats subjected to chronic stress, the peptide induced a cascade of molecular reactions that differed in animals with different resistance to emotional stress.
Improvement of mitochondrial function — Studies have shown that DSIP increases the respiratory control ratio (RCR) and the rate of ADP phosphorylation in brain mitochondria. Under hypoxic conditions, preincubation with DSIP completely inhibited the stress-induced reduction of mitochondrial respiratory activity.
Research on DSIP covers its potential influence on sleep, stress, pain, and metabolic and endocrine functions.
Sleep induction and insomnia
In the first human study from 1983 (Schneider-Helmert and Schoenenberger), intravenous infusion of DSIP (25 nmol/kg) in healthy volunteers produced an immediate sensation of sleep pressure, and total sleep time increased by 59% during the 130 minutes after administration. Delayed effects on nocturnal sleep included shorter sleep latency, a reduced percentage of stage 1 sleep, and better sleep efficiency. In a double-blind study in 16 patients with chronic insomnia, the results indicated higher sleep efficiency and shorter sleep latency with DSIP compared with placebo, although the effects were moderate.
Open clinical studies
In an open study of 7 patients with severe insomnia treated with a series of 10 DSIP injections, normalization of sleep was achieved in 6 of 7 individuals over follow-up periods of 3-7 months. Improvements in mood and daytime performance were also observed.
Analgesic action
Pilot clinical studies in patients with chronic pain episodes (migraine, vasomotor headaches, chronic tinnitus, psychogenic pain attacks) showed that DSIP significantly reduced pain levels in 6 of 7 patients after intravenous administration for 5 consecutive days. A significant reduction in coexisting depressive states was observed at the same time.
Protection against stress and hypoxia
In studies in rats, preincubation with DSIP (120 μg/kg) before exposure to hypoxia completely inhibited the stress-induced reduction of respiratory activity in brain mitochondria. The peptide showed the ability to increase the efficiency of oxidative phosphorylation in vitro, which may contribute to the stress-protective and antioxidant action observed in vivo.
Fusion systems and improvement of bioavailability
A 2024 study (Mu et al.) described the development of DSIP fusion peptides with sequences crossing the blood-brain barrier (DSIP-CBBBP) secreted by the yeast Pichia pastoris. In a PCPA-induced insomnia model in mice, the fusion peptides showed potential for improving sleep and balancing neurotransmitter levels.
DSIP remains one of the most enigmatic molecules in neurobiology. Despite nearly half a century of research, its physiological role has not been unequivocally established. The peptide is distinguished by several features:
From a historical perspective, DSIP was considered a candidate sleep-inducing factor, but this hypothesis has never been fully confirmed. Currently, the existence of a “DSIP-like peptide” is postulated, which may be responsible for the observed immunoreactivity and biological activity attributed to DSIP.
Research also suggests an association of DSIP with depression (altered levels in plasma and cerebrospinal fluid in patients with severe depression), adipogenesis (expression of homologous GILZ is associated with obesity), and epilepsy (anticonvulsant action in animal models).
General tolerance — In clinical studies conducted mainly in the 1980s, DSIP was generally well tolerated. No serious adverse effects were reported at the doses used in research protocols.
Adverse effects — Occasionally observed symptoms included: transient headaches, dizziness, mild gastrointestinal disturbances, and temporary feelings of fatigue or agitation.
Pharmacokinetic limitations — The main challenge is the very short half-life of DSIP (about 15 minutes) due to rapid enzymatic degradation. This limits bioavailability and requires the development of stabilized analogues or advanced delivery systems.
Interactions — Studies indicate interactions of DSIP with endogenous opioid systems and with exogenously administered morphine and amphetamine. Effects on MAO-A activity and circadian rhythms suggest a potential for interactions with psychotropic drugs.
Regulatory status — DSIP is not approved by any major regulatory agency (FDA, EMA) for clinical use. The peptide remains a research substance without an established safety profile for long-term use in humans. It is available as a research peptide for scientific purposes.
